Payment overview · 2025
General Payments
$808.42
21 reported records · 11 companies
Healthcare provider profile · identity verified
Mohammad A Chaudhry, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · UNION CITY, NJ · NPI 1033119573
Verified facts
What the public records show
CMS Open Payments records show Mohammad A Chaudhry, M.D. received $808.42 in general payments during 2025 across 21 reported records.
AstraZeneca Pharmaceuticals LP accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Mounjaro, Ozempic, Rybelsus.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 1822 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 290 claims for Symbicort by this doctor in 2024.
Azurity Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EDARBYCLOR as an associated drug or biological on 283 records involving 215 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Edarbyclor by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 427 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 427 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 436 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 389 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $288.75 | 35.7% | 8 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$170.99 | 21.1% | 1 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $126.38 | 15.6% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.41 | 6.4% | 3 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $45.55 | 5.6% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $34.71 | 4.3% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.54 | 3.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $17.57 | 2.2% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.69 | 2.1% | 1 | 2025 |
| Validus Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $16.08 | 2.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.75 | 1.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $808.42 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $226.26 | 4 | 2025 |
Source payment records
|
|||||
| COBALT DR MRI SURESCAN Normalized: cobalt dr mri surescan |
Device | Medtronic, Inc. | $170.99 | 1 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $126.38 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $103.01 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.41 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.41 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $45.55 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $45.55 | 2 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $34.71 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.54 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| HORIZANT Normalized: horizant |
Drug | Azurity Pharmaceuticals, Inc. | $16.69 | 1 | 2025 |
Source payment records
|
|||||
| RALDESY Normalized: raldesy |
Drug | Validus Pharmaceuticals LLC | $16.08 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 1822 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 427 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 436 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 389 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
1822 | 436 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
290 | 90 |
| Azurity Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | EDARBYCLOR open payments reported associated product |
CMS Open Payments — General Payments 283 supporting records · 215 recipient NPIs · example record 1242666846 |
Edarbyclor · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
427 | 87 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
427 | 87 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
436 | 87 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
91 | 22 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
389 | 59 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 2640 | 770 |
| Farxiga | Dapagliflozin Propanediol | 1822 | 436 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 1752 | 527 |
| Metformin Hcl | Metformin Hcl | 1729 | 489 |
| Montelukast Sodium | Montelukast Sodium | 1423 | 418 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 1346 | 405 |
| Amlodipine Besylate | Amlodipine Besylate | 1305 | 386 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1294 | 368 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 1137 | 299 |
| Omeprazole | Omeprazole | 1116 | 311 |
| Levothyroxine Sodium | Levothyroxine Sodium | 1099 | 284 |
| Losartan Potassium | Losartan Potassium | 869 | 246 |
| Diclofenac Sodium | Diclofenac Sodium | 756 | 168 |
| Fluticasone Propionate | Fluticasone Propionate | 746 | 240 |
| Gabapentin | Gabapentin | 729 | 185 |
| Metoprolol Succinate | Metoprolol Succinate | 712 | 222 |
| Vascepa | Icosapent Ethyl | 664 | 160 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 608 | 137 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 599 | 175 |
| Glimepiride | Glimepiride | 597 | 159 |
| Azithromycin | Azithromycin | 580 | 418 |
| Meclizine Hcl | Meclizine Hcl | 576 | 179 |
| Famotidine | Famotidine | 535 | 153 |
| Azelastine Hcl | Azelastine Hcl | 499 | 170 |
| Carvedilol | Carvedilol | 488 | 126 |
| Alendronate Sodium | Alendronate Sodium | 461 | 120 |
| Trazodone Hcl | Trazodone Hcl | 441 | 122 |
| Mounjaro | Tirzepatide | 436 | 87 |
| Jardiance | Empagliflozin | 427 | 87 |
| Tamsulosin Hcl | Tamsulosin Hcl | 420 | 117 |
| Januvia | Sitagliptin Phosphate | 419 | 87 |
| Pantoprazole Sodium | Pantoprazole Sodium | 403 | 107 |
| Ozempic | Semaglutide | 389 | 59 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 385 | 118 |
| Sertraline Hcl | Sertraline Hcl | 382 | 125 |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 379 | 109 |
| Donepezil Hcl | Donepezil Hcl | 376 | 108 |
| Methylprednisolone | Methylprednisolone | 328 | 273 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 314 | 108 |
| Linzess | Linaclotide | 298 | 68 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 296 | 83 |
| Symbicort | Budesonide/Formoterol Fumarate | 290 | 90 |
| Ibandronate Sodium | Ibandronate Sodium | 288 | 84 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 267 | 75 |
| Furosemide | Furosemide | 258 | 62 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 255 | 212 |
| Meloxicam | Meloxicam | 253 | 109 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 239 | 50 |
| Hydrochlorothiazide | Hydrochlorothiazide | 236 | 63 |
| Clopidogrel | Clopidogrel Bisulfate | 234 | 64 |
| Eliquis | Apixaban | 232 | 48 |
| Hydrocortisone | Hydrocortisone | 232 | 82 |
| Memantine Hcl | Memantine Hcl | 211 | 45 |
| Valsartan | Valsartan | 208 | 62 |
| Simvastatin | Simvastatin | 200 | 66 |
| Metoprolol Tartrate | Metoprolol Tartrate | 195 | 55 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 189 | 47 |
| Ammonium Lactate | Ammonium Lactate | 186 | 30 |
| Promethazine Hcl | Promethazine Hcl | 161 | 133 |
| Icosapent Ethyl | Icosapent Ethyl | 160 | 66 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 157 | 29 |
| Atenolol | Atenolol | 152 | 37 |
| Lisinopril | Lisinopril | 146 | 55 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 145 | 59 |
| Fenofibrate | Fenofibrate | 142 | 34 |
| Escitalopram Oxalate | Escitalopram Oxalate | 141 | 39 |
| Allopurinol | Allopurinol | 140 | 28 |
| Glipizide | Glipizide | 140 | 32 |
| Pravastatin Sodium | Pravastatin Sodium | 139 | 36 |
| Finasteride | Finasteride | 138 | 35 |
| Ventolin Hfa | Albuterol Sulfate | 132 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 127 | 82 |
| Clonidine Hcl | Clonidine Hcl | 126 | 29 |
| Alcohol Pads | Alcohol Antiseptic Pads | 120 | 30 |
| Hydralazine Hcl | Hydralazine Hcl | 115 | 28 |
| Ezetimibe | Ezetimibe | 111 | 32 |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 109 | 36 |
| Fluocinonide | Fluocinonide | 109 | 28 |
| Pro Comfort Alcohol Pads | Alcohol Antiseptic Pads | 105 | 33 |
| Dapagliflozin | Dapagliflozin Propanediol | 104 | 76 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 100 | 27 |
| Metformin Hcl Er | Metformin Hcl | 100 | 38 |
| Breo Ellipta | Fluticasone/Vilanterol | 98 | 19 |
| Candesartan Cilexetil | Candesartan Cilexetil | 97 | 24 |
| Repaglinide | Repaglinide | 97 | 21 |
| Lidocaine | Lidocaine | 96 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 92 | 28 |
| Trulicity | Dulaglutide | 91 | 22 |
| Valacyclovir | Valacyclovir Hcl | 91 | 31 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 89 | 25 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 89 | 23 |
| Mupirocin | Mupirocin | 87 | 39 |
| Procto-Med Hc | Hydrocortisone | 87 | 23 |
| Levofloxacin | Levofloxacin | 84 | 81 |
| Tradjenta | Linagliptin | 84 | 18 |
| Entresto | Sacubitril/Valsartan | 83 | 20 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 80 | 37 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 75 | 13 |
| Mirtazapine | Mirtazapine | 75 | 22 |
| Ibuprofen | Ibuprofen | 69 | 25 |
| Ciclopirox | Ciclopirox | 62 | 16 |
| Glipizide Er | Glipizide | 62 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 62 | 28 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 61 | 19 |
| Metformin Er Gastric | Metformin Hcl | 61 | 21 |
| Proctozone-Hc | Hydrocortisone | 59 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 58 | 53 |
| Naproxen | Naproxen | 57 | 22 |
| Potassium Chloride | Potassium Chloride | 57 | 14 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 56 | 13 |
| Clobetasol Propionate | Clobetasol Propionate | 56 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 56 | 16 |
| Lansoprazole | Lansoprazole | 56 | 18 |
| Risedronate Sodium | Risedronate Sodium | 56 | 11 |
| Ranolazine Er | Ranolazine | 54 | 12 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 44 |
| Dexlansoprazole Dr | Dexlansoprazole | 53 | 16 |
| Nateglinide | Nateglinide | 53 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 51 | 13 |
| Alcohol Swabs | Alcohol Antiseptic Pads | 50 | 23 |
| Methimazole | Methimazole | 50 | 13 |
| Metronidazole | Metronidazole | 50 | 36 |
| Xarelto | Rivaroxaban | 50 | 15 |
| Ketoconazole | Ketoconazole | 49 | 17 |
| Labetalol Hcl | Labetalol Hcl | 49 | 15 |
| Prolia | Denosumab | 49 | 27 |
| Enalapril Maleate | Enalapril Maleate | 45 | 15 |
| Memantine Hcl Er | Memantine Hcl | 45 | 11 |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 44 | suppressed |
| Irbesartan | Irbesartan | 42 | 12 |
| Levetiracetam | Levetiracetam | 42 | 11 |
| Warfarin Sodium | Warfarin Sodium | 41 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 39 | suppressed |
| Latanoprost | Latanoprost | 38 | suppressed |
| Myrbetriq | Mirabegron | 38 | suppressed |
| Novolog Flexpen | Insulin Aspart | 38 | suppressed |
| Synthroid | Levothyroxine Sodium | 38 | suppressed |
| Amlodipine-Atorvastatin | Amlodipine/Atorvastatin | 37 | suppressed |
| Single Use Swab | Alcohol Antiseptic Pads | 36 | 15 |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 35 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 35 | 31 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 34 | 15 |
| Paroxetine Hcl | Paroxetine Hcl | 34 | 11 |
| Terconazole | Terconazole | 34 | 25 |
| Livalo | Pitavastatin Calcium | 33 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | suppressed |
| Ramipril | Ramipril | 32 | 11 |
| Clarithromycin | Clarithromycin | 31 | 27 |
| Humalog Kwikpen U-100 | Insulin Lispro | 31 | 14 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 31 | suppressed |
| Betamethasone Valerate | Betamethasone Valerate | 29 | suppressed |
| Comfort Ez Pen Needle | Pen Needle, Diabetic | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Clotrimazole | Clotrimazole | 28 | suppressed |
| Omeprazole-Sodium Bicarbonate | Omeprazole/Sodium Bicarbonate | 28 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 27 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 22 |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 27 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 26 | suppressed |
| Desloratadine | Desloratadine | 26 | suppressed |
| Easy Touch Alcohol Prep Pads | Alcohol Antiseptic Pads | 26 | 14 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 23 | suppressed |
| Creon | Lipase/Protease/Amylase | 23 | suppressed |
| Clonidine | Clonidine | 22 | suppressed |
| Ramelteon | Ramelteon | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Lubiprostone | Lubiprostone | 21 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 20 | suppressed |
| Cephalexin | Cephalexin | 20 | 19 |
| Halobetasol Propionate | Halobetasol Propionate | 20 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 19 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 19 | suppressed |
| Folic Acid | Folic Acid | 19 | suppressed |
| Amlodipine-Olmesartan | Amlodipine Bes/Olmesartan Med | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Lumigan | Bimatoprost | 18 | suppressed |
| Nitroglycerin | Nitroglycerin | 18 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 17 | suppressed |
| Edarbyclor | Azilsartan Med/Chlorthalidone | 17 | suppressed |
| Epinephrine | Epinephrine | 17 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 17 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 16 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Econazole Nitrate | Econazole Nitrate | 15 | suppressed |
| Nabumetone | Nabumetone | 15 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 15 | suppressed |
| Pregabalin | Pregabalin | 15 | suppressed |
| Restasis | Cyclosporine | 15 | suppressed |
| Telmisartan | Telmisartan | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 14 | suppressed |
| Donepezil Hcl Odt | Donepezil Hcl | 14 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 14 | 13 |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Silodosin | Silodosin | 14 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 13 | suppressed |
| Amlodipine-Valsartan-Hctz | Amlodipine/Valsartan/Hcthiazid | 13 | suppressed |
| Aripiprazole | Aripiprazole | 13 | suppressed |
| Atenolol-Chlorthalidone | Atenolol/Chlorthalidone | 13 | suppressed |
| Enulose | Lactulose | 13 | suppressed |
| Loperamide | Loperamide Hcl | 13 | 11 |
| Meloxicam | Meloxicam, Submicronized | 13 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Rivastigmine | Rivastigmine | 13 | suppressed |
| Sucralfate | Sucralfate | 13 | suppressed |
| Acarbose | Acarbose | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 12 | suppressed |
| Dabigatran Etexilate | Dabigatran Etexilate Mesylate | 12 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 12 | suppressed |
| Niacin Er | Niacin | 12 | suppressed |
| Primidone | Primidone | 12 | suppressed |
| Sotalol | Sotalol Hcl | 12 | suppressed |
| Spironolactone | Spironolactone | 12 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Zafirlukast | Zafirlukast | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Azathioprine | Azathioprine | 11 | suppressed |
| Calcipotriene | Calcipotriene | 11 | suppressed |
| Ciprofloxacin-Dexamethasone | Ciprofloxacin Hcl/Dexameth | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 11 | suppressed |
| Fluconazole | Fluconazole | 11 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 11 | suppressed |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $808.42 · 21 records | AstraZeneca Pharmaceuticals LP | BREZTRI, COBALT DR MRI SURESCAN, Da Vinci Surgical System, FARXIGA, HORIZANT, JARDIANCE, Kerendia, Korlym, MOUNJARO, Ozempic, RALDESY, Rybelsus, The Cologuard Plus Collection Kit, ZEPBOUND | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error